Trial Profile
Efficacy and Safety of Durvalumab Combined With Intrathecal Chemotherapy in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Jun 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Methotrexate (Primary)
- Indications Meningeal carcinomatosis; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 22 May 2020 Planned number of patients changed from 40 to 30.
- 22 May 2020 Planned End Date changed from 1 Apr 2023 to 1 Jun 2023.
- 22 May 2020 Planned primary completion date changed from 1 Apr 2023 to 1 Jun 2023.